Effect of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy on Severe Exacerbation Rates Compared With Twice-Daily Budesonide/Formoterol Dual Therapy in Patients With Copd: A Post Hoc Analysis of the Fulfil Study

Abstract

FULFIL evaluated once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus twicedaily budesonide/formoterol (BUD/FOR) inhaled corticosteroid/long-acting b2-agonist (ICS/LABA) dual therapy in patients with symptomatic chronic obstructive pulmonary disease (COPD) who were at risk of exacerbations. FULFIL showed clinically meaningful and statistically significant improvements in lung function and health-related quality of life, as well as reductions in moderate/severe exacerbation annualized rates in patients receiving FF/UMEC/VI versus those receiving BUD/FOR. Severe exacerbations place a high clinical and financial burden on both patients and healthcare systems. This post hoc analysis examined treatment effects on severe exacerbation rates in the FULFIL study.